12月4日港股创新药ETF（513120）份额增加2300.00万份

Core Insights - The Hong Kong Innovative Drug ETF (513120) increased by 1.99% on December 4, with a trading volume of 4.785 billion yuan [1] - The fund's shares rose by 23 million to a total of 1.8832 billion shares, with an increase of 541 million shares over the past 20 trading days [1] - The latest net asset value of the fund is 25.204 billion yuan [1] - The fund's performance benchmark is the return of the CSI Hong Kong Innovative Drug Index (in RMB), managed by Guangfa Fund Management Co., Ltd. [1] - Since its inception on July 1, 2022, the fund has achieved a return of 33.83%, with a return of 0.35% over the past month [1]